Progesterone Receptor Negative Recruiting Phase 2 Trials for Exemestane (DB00990)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02648477Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast CancerTreatment